Sign inJoin waitlistJoin the waitlist

Paul Zolkind

Chief of Otolaryngology, John Cochran VA Medical Center · Washington University/B-JH/SLCH Consortium

Credentials: · · · ·

History

John Cochran VA Medical Center Division · Washington University/B-JH/SLCH Consortium
Present
Washington University/B-JH/SLCH Consortium · Washington University School of Medicine
Present

Stanford University
2020–2021
Otolaryngology – Head and Neck Surgery
Washington University School of Medicine
2015–2020
SUNY Downstate College of Medicine
2009–2013
Northwestern University
2009
Resident
Washington University School of Medicine

Research

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Clinical Cancer Research · 2020 · 335 citations
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells
Clinical Cancer Research · 2020 · 81 citations
Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial
Clinical Cancer Research · 2017 · 44 citations

Patrik Pipkorn
25 papers
Ryan Jackson
24 papers
Sidharth Puram
22 papers
Jason Rich
18 papers
Douglas Adkins
16 papers
Alex Harbison
14 papers
Randal Paniello
13 papers
Ravindra Uppaluri
13 papers
Wade Thorstad
12 papers
Peter Oppelt
9 papers
SR
Salma Ramadan
8 papers · 6 as a resident
Thomas Barrett
8 papers · 8 as a resident

Grants

Targeting NRF2 in Head and Neck Squamous Cell Carcinoma
Department of Veterans Affairs · IK2
Contact PI · St. Louis Va Medical Center
2023–2027

Clinical trials

Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma
Principal investigator · Completed · Early phase 1
Washington University School of Medicine
2023–2025
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Sub-investigator · Not yet recruiting · Phase 1, Phase 2
Washington University School of Medicine
2026–2033
Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
Sub-investigator · Recruiting · Phase 2
Washington University School of Medicine
2021–2027